Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17499 clinical trials
Clinical and Genomic Predictors of Progression to Myeloma in Patients With Asymptomatic Monoclonal Gammopathies

The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as …

amyloidosis
gammopathy
monoclonal antibodies
bone marrow plasma cells
multiple myeloma
  • 0 views
  • 26 Jan, 2022
  • 1 location
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients

This study is to assess for Measurable Residual Disease (MRD) in multiple myeloma at a deeper level than what is currently available by combining novel imaging and laboratory techniques, determine if patients who are MRD-negative by these multiple modalities can safely and effectively discontinue post-transplant maintenance therapy, and determine if …

cancer
bortezomib
ixazomib
pomalidomide
lenalidomide
  • 22 views
  • 04 Mar, 2022
  • 1 location
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting …

measurable disease
bortezomib
daratumumab
bone marrow procedure
carfilzomib
  • 0 views
  • 15 Oct, 2021
  • 1 location
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

Newly diagnosed Multiple Myeloma patients who are ineligible for a transplant have inferior outcomes to that of the transplant population. This is an area of high unmet need and calls for newer therapies with novel mechanisms of action to improve survival in this non-transplant eligible (NTE) group. Daratumumab is a …

bortezomib
lenalidomide
monoclonal protein
daratumumab
melphalan
  • 15 views
  • 24 Jan, 2021
  • 2 locations
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered intravenously at 2.5 milligram (mg)/kilogram …

cancer
ejection fraction
pomalidomide
lenalidomide
proteasome inhibitor
  • 5 views
  • 16 Mar, 2022
  • 140 locations
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 …

daratumumab
induction therapy
heparin
warfarin
lenalidomide
  • 216 views
  • 04 Mar, 2022
  • 543 locations
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.

induction therapy
  • 0 views
  • 17 Feb, 2021
  • 4 locations
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma

bcma
ejection fraction
fludarabine
refractory multiple myeloma
immunohistochemistry
  • 0 views
  • 25 Jan, 2021
  • 2 locations
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-BCMA CAR-T cells for the treatment of multiple myeloma

  • 0 views
  • 31 Jan, 2021
  • 1 location
Daratumumab Carfilzomib Pomalidomide Dexamethasone In MM

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of …

colony stimulating factor
lenalidomide
platelet count
filgrastim
carfilzomib
  • 0 views
  • 05 Nov, 2021
  • 3 locations